Advances in the basic research on traditional Chinese medicine for prevention and treatment of hepatic fibrosis based on omics technology

Jianzhi WU; Bin HUANG; Jincheng GUO; Zhiyun YANG; Xiaojiaoyang LI

Return

Advances in the basic research on traditional Chinese medicine for prevention and treatment of hepatic fibrosis based on omics technology

VernacularTitle:基于组学技术的中医药防治肝纤维化基础研究进展
Author: Jianzhi WU ¹ ; Bin HUANG ² ; Jincheng GUO ³ ; Zhiyun YANG ⁴ ; Xiaojiaoyang LI ⁵
Author Information

1. Frontiers Medical Center， Tianfu Jincheng Laboratory， Chengdu 610212， China
2. Institute of Integrated Chinese and Western Medicine， Fujian University of Traditional Chinese Medicine， Fuzhou 350122， China
3. School of Traditional Chinese Medicine， Beijing University of Chinese Medicine， Beijing 100029， China
4. Second Department of Integrated Traditional Chinese and Western Medicine， Beijing Ditan Hospital， Capital Medical University， Beijing 100015， China
5. School of Life Sciences Beijing University of Chinese Medicine Beijing 100029， China
Publication Type:Journal Article
Keywords: Hepatic Fibrosis; Anti-Hepato Fibrosis Agents （TCD）; Transcriptomics; Proteomics; Metabolomics
From: Journal of Clinical Hepatology 2025;41(10):1988-1993
CountryChina
Language:Chinese
Abstract: Hepatic fibrosis is the common key pathological link of various chronic liver diseases and can progress to malignant diseases such as liver cirrhosis and hepatocellular carcinoma； however， there is still a lack of effective targeted therapeutic drugs at present. Traditional Chinese medicine （TCM） has a marked clinical effect in the prevention and treatment of hepatic fibrosis， yet its precise clinical application and global promotion are greatly limited by the complex components of compound prescriptions and unclear mechanism of action. In recent years， multimodal high-throughput omics technology has achieved rapid development， providing strong technical support for elaborating on the scientific connotation of TCM in the treatment of complex diseases due to its advantages of systematic profiling， big-data analytics， and precise target prediction. In particular， integrated transcriptomic， proteomic， and metabolomic strategies comprehensively elucidate key signaling networks， cellular phenotypic transitions， and extracellular matrix metabolic homeostasis modulated by TCM compounds and monomers and assist in the screening and assessment of effective component groups and novel biomarkers. This article systematically reviews the advances in basic research on TCM prevention and treatment of hepatic fibrosis based on multi-omics technologies in the past five years， summarizes the “drug-target-pathway-phenotype” regulatory network， and elaborates on the core mechanisms of TCM in regulating hepatic stellate cell activation and reversing hepatic fibrosis. Future studies should further delve into the interdisciplinary integration and dynamic analytical methodologies of multi-omics technologies， precisely identify the core regulatory target networks modulated by TCM， and systematically unravel the scientific connotation of compatibility rule in compound prescriptions， in order to provide a theoretical basis for developing efficient targeted drugs for hepatic fibrosis and individualized diagnosis and treatment strategies.